Search

A study published in the European Journal of Heart Failure compared the effectiveness of sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB) in patients with newly diagnosed heart failure (HF) and preserved or mildly reduced ejection fraction. The study used a large real-world dataset from the United States and found that patients initiated on sacubitril/valsartan had significantly lower rates of all-cause and cardiovascular hospitalizations compared to those initiated on ACEi/ARB. These findings support the potential benefit of early initiation of sacubitril/valsartan in a diverse and high-risk HF population. However, the study acknowledges limitations, including its retrospective nature and the possibility of unmeasured confounding. The study was funded by Novartis AG, and some of the authors reported conflicts of interest. [Extracted from the article]

Survival after out-of-hospital cardiopulmonary arrest is estimated at less than 5%. We report a case of ventricular fibrillation during sports activity. Cardiopulmonary resuscitation was initiated early by a layperson, and defibrillation was successfully performed within less than three minutes, with an automated external defibrillator. The public access to defibrillation programs has increased the survival after out-of-hospital ventricular fibrillation. We should encourage the training of laypeople in relation to the use of automated external defibrillators and the Basic Life Support program by stimulating their implementation in places where large numbers of people gather or where people are at a high risk of sudden death, as is the case of sports centers.